- Home
- CRSP vs ASB Comparison
CRSP vs ASB Comparison
Compare CRSP & ASB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- ASB
- Stock Information
- Founded
- CRSP 2013
- ASB 1861
- Country
- CRSP Switzerland
- ASB United States
- Employees
- CRSP N/A
- ASB N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- ASB Major Banks
- Sector
- CRSP Health Care
- ASB Finance
- Exchange
- CRSP Nasdaq
- ASB Nasdaq
- Market Cap
- CRSP 4.9B
- ASB 3.4B
- IPO Year
- CRSP 2016
- ASB N/A
- Fundamental
- Price
- CRSP $57.68
- ASB $25.17
- Analyst Decision
- CRSP Buy
- ASB Hold
- Analyst Count
- CRSP 16
- ASB 11
- Target Price
- CRSP $70.73
- ASB $27.64
- AVG Volume (30 Days)
- CRSP 3.7M
- ASB 1.7M
- Earning Date
- CRSP 08-04-2025
- ASB 07-24-2025
- Dividend Yield
- CRSP N/A
- ASB 3.63%
- EPS Growth
- CRSP N/A
- ASB N/A
- EPS
- CRSP N/A
- ASB 0.78
- Revenue
- CRSP $37,675,000.00
- ASB $1,035,964,000.00
- Revenue This Year
- CRSP $28.31
- ASB $54.38
- Revenue Next Year
- CRSP $268.05
- ASB $6.05
- P/E Ratio
- CRSP N/A
- ASB $32.34
- Revenue Growth
- CRSP N/A
- ASB 3.82
- 52 Week Low
- CRSP $30.04
- ASB $18.32
- 52 Week High
- CRSP $71.13
- ASB $28.18
- Technical
- Relative Strength Index (RSI)
- CRSP 52.32
- ASB 50.97
- Support Level
- CRSP $61.13
- ASB $25.07
- Resistance Level
- CRSP $69.58
- ASB $25.82
- Average True Range (ATR)
- CRSP 3.89
- ASB 0.56
- MACD
- CRSP -0.71
- ASB -0.13
- Stochastic Oscillator
- CRSP 28.46
- ASB 25.37
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About ASB Associated Banc-Corp
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.